GLPG 3970
Alternative Names: GLPG-3970Latest Information Update: 04 Jul 2025
At a glance
- Originator Galapagos NV
- Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Skin disorder therapies; Small molecules
- Mechanism of Action Salt-inducible kinase 3 inhibitors; Salt-inducible kinase-2 inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Inflammatory bowel diseases; Psoriasis; Rheumatoid arthritis; Sjogren's syndrome; Systemic lupus erythematosus; Ulcerative colitis; Unspecified
Most Recent Events
- 12 Oct 2024 Pharmacodynamics data from the preclinical data in Inflammatory bowel disease at the 32nd United European Gastroenterology Week (UEGW-2024)
- 22 May 2023 SEC Filings 3785504- Profile made discontinued
- 28 Nov 2022 No recent reports of development identified for preclinical development in Inflammatory-bowel-diseases in Belgium